Theresa brings a range of expertise from her former role in the oncology group at Johnson & Johnson (J&J) Innovative Medicines (formerly Janssen), where she led programs from target validation through IND-readiness in the prostate cancer portfolio. Projects that entered clinical development under Theresa’s leadership include CD3 redirectors and CAR Ts for prostate-specific targets. Theresa also led the first co-stimulation/CD3 combination program at Janssen. Beyond T cell biology, Theresa also played a key role in building internal infrastructure and external relationships to advance radioconjugates. She is a co-inventor on 17 patents for the treatment of solid tumors, encompassing CD3, CD28, CAR T, radio-conjugates, and ADCCs.

Prior to Janssen, Theresa was part of the oncology discovery team at Bristol Myers Squibb (BMS), where she supported several small- and large-molecule programs, including epigenetic targets, DR5 agonists, and JAK2 inhibitors from target validation through first-in-human studies.

She received her PhD in pharmacology from the University of Sciences in Philadelphia.